Literature DB >> 25823383

Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy.

Amar U Kishan1, Minsong Cao1, Pin-Chieh Wang1, Argin G Mikaeilian1, Stephen Tenn1, Jean-Claude M Rwigema1, Ke Sheng1, Daniel A Low1, Patrick A Kupelian1, Michael L Steinberg1, Percy Lee2.   

Abstract

PURPOSE: The purpose of this study was to investigate the dosimetric feasibility of liver stereotactic body radiation therapy (SBRT) using a teletherapy system equipped with 3 rotating (60)Co sources (tri-(60)Co system) and a built-in magnetic resonance imager (MRI). We hypothesized tumor size and location would be predictive of favorable dosimetry with tri-(60)Co SBRT. METHODS AND MATERIALS: The primary study population consisted of 11 patients treated with SBRT for malignant hepatic lesions whose linear accelerator (LINAC)-based SBRT plans met all mandatory Radiation Therapy Oncology Group (RTOG) 1112 organ-at-risk (OAR) constraints. The secondary study population included 5 additional patients whose plans did not meet the mandatory constraints. Patients received 36 to 60 Gy in 3 to 5 fractions. Tri-(60)Co system SBRT plans were planned with ViewRay system software.
RESULTS: All patients in the primary study population had tri-(60)Co SBRT plans that passed all RTOG constraints, with similar planning target volume coverage and OAR doses to LINAC plans. Mean liver doses and V10Gy to the liver, although easily meeting RTOG 1112 guidelines, were significantly higher with tri-(60)Co plans. When the 5 additional patients were included in a univariate analysis, the tri-(60)Co SBRT plans were still equally able to pass RTOG constraints, although they did have inferior ability to pass more stringent liver and kidney constraints (P < .05). A multivariate analysis found the ability of a tri-(60)Co SBRT plan to meet these constraints depended on lesion location and size. Patients with smaller or more peripheral lesions (as defined by distance from the aorta, chest wall, liver dome, and relative lesion volume) were significantly more likely to have tri-(60)Co plans that spared the liver and kidney as well as LINAC plans did (P < .05).
CONCLUSIONS: It is dosimetrically feasible to perform liver SBRT with a tri-(60)Co system with a built-in MRI. Patients with smaller or more peripheral lesions are more likely to have optimal liver and kidney sparing, with the added benefit of MRI guidance, when receiving tri-(60)Co-based SBRT.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25823383     DOI: 10.1016/j.prro.2015.02.014

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  11 in total

Review 1.  Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.

Authors:  Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo
Journal:  Nat Rev Urol       Date:  2017-06-20       Impact factor: 14.432

2.  Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.

Authors:  Lauren Henke; Rojano Kashani; Deshan Yang; Tianyu Zhao; Olga Green; Lindsey Olsen; Vivian Rodriguez; H Omar Wooten; H Harold Li; Yanle Hu; Jeffrey Bradley; Clifford Robinson; Parag Parikh; Jeff Michalski; Sasa Mutic; Jeffrey R Olsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-08-31       Impact factor: 7.038

3.  A Novel Respiratory Motion Perturbation Model Adaptable to Patient Breathing Irregularities.

Authors:  Amy Yuan; Jie Wei; Carl P Gaebler; Hailiang Huang; Devin Olek; Guang Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-09-03       Impact factor: 7.038

4.  Quality of tri-Co-60 MR-IGRT treatment plans in comparison with VMAT treatment plans for spine SABR.

Authors:  Chang Heon Choi; So-Yeon Park; Jung-In Kim; Jin Ho Kim; Kyubo Kim; Joel Carlson; Jong Min Park
Journal:  Br J Radiol       Date:  2016-12-08       Impact factor: 3.039

5.  Treatment plan comparison between Tri-Co-60 magnetic-resonance image-guided radiation therapy and volumetric modulated arc therapy for prostate cancer.

Authors:  Jong Min Park; So-Yeon Park; Chang Heon Choi; Minsoo Chun; Jin Ho Kim; Jung-In Kim
Journal:  Oncotarget       Date:  2017-08-08

6.  Analysis of Magnetic Resonance Image Signal Fluctuations Acquired During MR-Guided Radiotherapy.

Authors:  Adrian L Breto; Kyle R Padgett; John C Ford; Deukwoo Kwon; Channing Chang; Martin Fuss; Radka Stoyanova; Eric A Mellon
Journal:  Cureus       Date:  2018-03-28

7.  Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR.

Authors:  Jong Min Park; Hong-Gyun Wu; Hak Jae Kim; Chang Heon Choi; Jung-In Kim
Journal:  Radiat Oncol       Date:  2019-06-13       Impact factor: 3.481

8.  Real-time Magnetic Resonance-guided Liver Stereotactic Body Radiation Therapy: An Institutional Report Using a Magnetic Resonance-Linac System.

Authors:  Aharon M Feldman; Ankit Modh; Carri Glide-Hurst; Indrin J Chetty; Benjamin Movsas
Journal:  Cureus       Date:  2019-09-26

9.  A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy.

Authors:  Stephen A Rosenberg; Lauren E Henke; Narek Shaverdian; Kathryn Mittauer; Andrzej P Wojcieszynski; Craig R Hullett; Mitchell Kamrava; James Lamb; Minsong Cao; Olga L Green; Rojano Kashani; Bhudatt Paliwal; John Bayouth; Paul M Harari; Jeffrey R Olsen; Percy Lee; Parag J Parikh; Michael Bassetti
Journal:  Adv Radiat Oncol       Date:  2018-08-23

10.  Hybrid Tri-Co-60 MRI radiotherapy for locally advanced rectal cancer: An in silico evaluation.

Authors:  Luca Boldrini; Elisa Placidi; Nicola Dinapoli; Luigi Azario; Francesco Cellini; Mariangela Massaccesi; Silvia Chiesa; Maria Antonietta Gambacorta; Gian Carlo Mattiucci; Danila Piccari; Stefania Teodoli; Marco De Spirito; Vincenzo Valentini
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2018-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.